CPT code 82017 represents a quantitative acylcarnitine analysis used to detect fatty acid oxidation disorders and assist in diagnosing organic acidurias. As a specialized clinical laboratory test, it supports diagnosis and management of inborn errors of metabolism with implications for pediatric and adult metabolic care. Nationally, access to accurate acylcarnitine testing influences timely diagnosis, treatment planning, and genetic counseling.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for ordering the test, typical sites of service, and practical billing considerations tied to this laboratory service. The publication also outlines common modifiers reported with laboratory services, discusses payer coverage themes, and highlights benchmarks and policy updates affecting laboratory reimbursement and prior authorization practices. Clinical interpretation basics and indications for testing are summarized to clarify appropriate utilization.

This executive summary is intended for a national audience of clinicians, laboratory managers, and billing professionals seeking concise guidance on the role and billing context of CPT code 82017.